GlobeNewswire by notified

Pixium Vision announces positive long-term follow-up scientific data on PRIMA implant from Prima System French feasibility study

Share

Pixium Vision announces positive long-term follow-up scientific data on PRIMA implant from
Prima System French feasibility study

  • PRIMA implant is well tolerated and safe in patients 36 months after implantation
  • Implant is highly stable with no lifetime deteriorations observed
  • PRIMA can potentially provide meaningful visual acuity improvement

Paris, France, 13.10.2021 – 07:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces positive long-term data from patients implanted with PRIMA, a state-of-the-art implantable chip. The data were presented at The Eye and The Chip – Virtual Event, held October 3-5, 2021.

Dr. Yannick Le Mer, Head of Vitreo-retinal Unit at Fondation Adolphe de Rothschild Hospital in Paris and Principal Investigator of the PRIMAvera pivotal study, commented: “I was delighted to present such positive scientific data about PRIMA, our proprietary breakthrough sub-retinal wireless implant. PRIMA can be implanted easily without causing severe or untreatable complications. Furthermore, the implant is shown to be reliable in patients for over 36 months post implantation. These encouraging results position Pixium’s PRIMA implant, and the whole Prima System, as a realistic potential solution for people who suffer fromloss of central vision due to dry age-related macular degeneration (DryAMD), a large patient population with no solutions to improve their low quality of life currently on the market.

PRIMA, Pixium’s proprietary subretinal implant for Atrophic Dry AMD, was shown in clinical trials to be easily and safely implanted in patients, thanks to the unique design of the implant itself and Pixium’s proprietary delivery system used for implantations (Figure 1).

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

In the French feasibility study, five patients were observed and followed for up to 36 months post implantation, demonstrating no implant lifetime failure. These observations are in line with in vitro reliability studies that showed the implants to be 100% reliable with pixels reliability of over 90%, for over 20 years.

Results from the feasibility study of compensation for blindness with the Prima System in patients with Dry AMD have shown:

  • A significant improvement of to up logMAR 0.9 in visual acuity
  • PRIMA implants are well tolerated and safe in the implanted subjects
  • Integration of natural and artificial vision
  • No decrease of residual natural visual acuity in any of the patients
  • Unprecedented improvement in daily reading tasks demonstrating the feasibility of living with PRIMA

Following the successful results of the French feasibility study, the PRIMA implants and Prima System entered PRIMAvera, a European pivotal study design. A total of 38 patients will be enrolled in PRIMAvera, an open label, baseline-controlled, nonrandomized, multi-center, prospective, single-arm confirmatory trial. The primary efficacy endpoint is the proportion of subjects with an improvement of visual acuity of logMAR 0.2 or more from baseline to 12 month and the primary safety endpoint is the number and severity of device and procedure related serious adverse events at 12 months follow-up. The study will include three years of follow-up, with assessment of the primary endpoints at 12 months after implantation.

The French feasibility study (NCT03333954) enrolled 5 patients who were implanted with the PRIMA sub-retinal implant in one eye. Following a successful rehabilitation process, implanted patients have shown significant improvement in visual acuity.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

For more information: To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.http://www.pixium-vision.com/fr

Follow us on To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.@PixiumVision; To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.facebook.com/pixiumvision

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.linkedin.com/company/pixium-vision

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

Contacts

Pixium Vision
Offer Nonhoff
Chief Financial Officer
investors@pixium-vision.com
+33 1 76 21 47 68
Media Relations

LifeSci Advisors
Sophie Baumont
sophie@lifesciadvisors.com
+33 6 27 74 74 49
Investor Relations
LifeSci Advisors
Guillaume van Renterghem
gvanrenterghem@lifesciadvisors.com
+41 76 735 01 31


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists18.10.2021 14:00:00 CEST | Press release

~ Discovery efforts will focus on small molecules with differentiated clinical profiles to harness the broad potential of orexin agonism across different indications~ ~ First time Schrödinger is applying its computational platform in an orexin agonist setting enabled by Orexia’s structural biology capabilities ~ NEW YORK, BOSTON and LONDON, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Schrödinger (Nasdaq: SDGR) and Centessa Pharmaceuticals plc (“Centessa”) (Nasdaq: CNTA), together with subsidiary Orexia Therapeutics (“Orexia”), today announced an exclusive collaboration focused on the discovery of novel therapeutics targeting the orexin-2 receptor (OX2R), which is known to play a role in a broad spectrum of sleep disorders including narcolepsy. The collaboration provides Orexia with substantial access to Schrödinger’s entire computational platform as well as Schrödinger’s extensive expertise in ultra-large-scale deployment of its technology. Orexia will leverage Schrödinger’s computational platfo

Saniona completes submission of manufacturing data for Tesomet capsules to U.S. FDA18.10.2021 14:00:00 CEST | Press release

PRESS RELEASE 18October 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announcedthat it has completed the submission of all information previously requested by the U.S. Food and Drug Administration (FDA) regarding its chemistry, manufacturing and controls (CMC) programfor Tesomet capsules. With this submission completed, Saniona expects to be able to initiate its Phase 2b clinical trials for Tesomet before the end of 2021, as planned. There are multiple potential advantages to offering Tesomet as a capsule rather than a tablet to people living with Prader-Willi syndrome or hypothalamic obesity. Some of these individuals have a tendency to chew tablets, which could disrupt the effectiveness of the fixed-dose combination of Tesomet’s active ingredients. The Tesomet capsules contain the two active ingredients as microspheres, which are expected to minimize the impact of chewing or biting. Additionally, capsules are generally easier t

Saniona slutför inlämningen till FDA av tillverkningsdata för Tesometkapslar18.10.2021 14:00:00 CEST | Pressemelding

PRESSMEDDELANDE 18 oktober 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att alla uppgifter som det amerikanska läkemedelsverket FDA tidigare begärt in om bolagets program för kemi, tillverkning och kontroll (CMC) avseende Tesometkapslar nu har lämnats in. I och med att dessa uppgifter lämnats in förväntas Saniona att enligt plan kunna inleda kliniska studier i Fas 2b med Tesomet innan utgången av 2021. Det finns ett flertal möjliga fördelar med att erbjuda Tesomet som kapsel istället för tablett till personer som lever med Prader-Willis syndrom eller hypotalamisk fetma. Vissa av dessa drabbade individer tenderar att tugga sönder tabletter, vilket skulle kunna påverka effekten av den fasta doskombinationen av Tesomets aktiva substanser negativt. Tesometkapslarna innehåller de två aktiva substanserna i form av mikrosfärer, vilket väntas minimera påverkan från tuggande och bitande. Kapslar är dessutom i all

Prosafe SE and subsidiary company Prosafe Rigs Pte. Ltd. - Update on Financial Restructuring18.10.2021 13:30:03 CEST | Press release

Reference is made to the earlier information provided about the ongoing financial process with the lenders, the latest in: (a) a press release dated 13 October 2021 in relation to Prosafe SE's and Prosafe Rigs Pte Ltd's ("PRPL") applications for the Singapore Court to approve the Schemes agreed at the Scheme Meetings of the Scheme Creditors, in HC/OS 997/2021 and HC/OS 998/2021 (the "Sanction Applications"); and (b) a press release dated 14 October 2021 in relation to Westcon Yards AS' confirmation of their formal support of the Schemes. At the hearing of the Sanction Applications on 18 October 2021, the Singapore Court sanctioned the Schemes and permitted the insertion of a new clause 8.4 in the Schemes (as mentioned in the press release dated 13 October 2021). Prosafe SE and PRPL will proceed to lodge copies of the orders made by the Singapore Court with the Accounting and Corporate Regulatory Authority of Singapore. Prosafe SE wishes to thank all parties involved for their support o

Skyharbour Signs Option Agreement with Black Shield Metals Corp to Option 75% of the Mann Lake Uranium Project18.10.2021 13:00:00 CEST | Press release

VANCOUVER, British Columbia, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH)(OTCQB: SYHBF) (Frankfurt: SC1P) (“Skyharbour” or the “Company”) is pleased to announce that it has entered into an option agreement (the “Option Agreement”) with Black Shield Metals Corp. (CSE: BDX) (“Black Shield”) which provides Black Shield an earn-in option to acquire up to a 75% interest (the “Option”) in the Mann Lake Uranium Project (“Mann Lake” or the “Property”) located in the Athabasca Basin, Northern Saskatchewan, Canada. Mann Lake Project Location Map: https://skyharbourltd.com/_resources/SYH_Mann_Lake_Tenure.jpg Under the Option Agreement, Black Shield will contribute cash and exploration expenditure consideration totaling CAD $4,850,000 over a three-year period (“Project Consideration”). Of the Project Consideration, $850,000 will be in cash payments to Skyharbour and $4,000,000 will be in exploration expenditures on the project. Black Shield will also issue to Skyharbour

Hexagon Purus to join the ZeroCoaster project study, collaborating with leading partners to explore and develop the hydrogen value chain for maritime applications18.10.2021 13:00:00 CEST | Press release

Hexagon Purus joins the work package Zero Emission Compressed Hydrogen (ZECH) which is part of the ZeroCoaster project study coordinated by Vard, a major global ship design and shipbuilding company. This study aims to research, evaluate and present zero emission ship design solutions using alternative fuel systems. The ZeroCoaster represents coastal bulk cargo operations in Norway. Systems and component solutions revealed in the project are applicable for scaling and reconfiguring for other maritime applications. The project study is funded by The Research Council of Norway. One of the main objectives is to evaluate and challenge bunkering technologies and logistics operations, with a focus on safety, cost, and capacity. Hexagon Purus will contribute with its knowledge and expertise in storage and distribution of compressed hydrogen gas using Type 4 composite cylinder technology. Sharing knowledge to accelerate zero emission maritime solutions Norway has set a target to reduce emission

Nokia selected by T-2 Slovenia in five-year 5G deal as sole supplier18.10.2021 10:00:00 CEST | Press release

Press Release Nokia selected by T-2 Slovenia in five-year 5G deal as sole supplier Nokia to expand T-2’s Single RAN footprint and introduce enhanced 5G services across the country 18 October 2021 Espoo, Finland – Nokia today announced that it has been selected as the sole vendor by Slovenia’s T-2 in a five-year deal to supply equipment from its comprehensive AirScale 5G portfolio. The new deal will see Nokia upgrade T-2’s existing Single RAN radio footprint as well as introduce enhanced 5G new radio (NR) services. The project is expected to deliver ultra-fast, low-latency, and high-capacity 5G connectivity delivering superior coverage to businesses and consumers alike. Nokia will provide equipment from its latest AirScale radio portfolio, all powered by Nokia's energy-efficient ReefShark System-on-Chip technology. This includes 5G RAN, AirScale base stations, and Nokia AirScale radio access products including its Single RAN portfolio for both indoor and outdoor coverage. These solution